Chargement en cours...
Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
Lenalidomide is an oral immunomodulatory agent approved in relapsed multiple myeloma with dexamethasone, for transfusion-dependent anemia in myelodysplastic syndrome associated with deletion 5q, and in relapsed/progressive mantle cell lymphoma following bortezomib. In recent clinical trials, lenalid...
Enregistré dans:
| Publié dans: | J Adv Pract Oncol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Harborside Press
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4457182/ https://ncbi.nlm.nih.gov/pubmed/26110071 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|